DE-W.-L.-GORE
21.1.2019 09:02:07 CET | Business Wire | Press release
W. L. Gore & Associates, Inc. (Gore) today introduced reduced profiles for the most commonly used diameters of the GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System. The reduced profile allows physicians to perform TEVAR in patients with smaller vessels where access is challenging and aortic anatomy is tortuous, expanding the availability of Gore’s thoracic stent graft to a greater population of patients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190121005042/en/
The GORE® TAG® Conformable Thoracic Stent Graft was modified to reduce the delivery profile of the 31, 37, and 40 mm device diameters by 2 Fr for all lengths. The reduction in profile, through the use of a smaller diameter primary sleeve, is the only change to the device. The stent graft leverages the same predictable outcomes of the time-tested Conformable GORE® TAG® Device, which has established long-term freedom from reintervention (93.1%), low complication rates, with zero migrations, fractures, or compressions.* and a low 2.4% access site complication rate for endovascular treatment of the descending thoracic aorta.** The new profiles also continue to feature the same unique combination of proprietary ePTFE graft material and a fully supported, nested, nitinol stent.
“As the market for TEVAR has continued to expand and evolve, lower profile devices have rapidly emerged with a goal of increased patient applicability, accessibility, trackability and finally reducing access complications for patients with smaller vessels ,” said Professor Boeckler. “It’s reassuring that the new reduced profile sizes of the GORE® TAG® Conformable Thoracic Stent Graft was achieved without changes to the stent graft. Gore’s device is known for its conformability, and the GORE ACTIVE CONTROL System enables me to take full advantage of the conformability by allowing precise placement during TEVAR procedures. The combination of controlled delivery with the trusted stent graft, and now reduced profile for the device, is a significant advancemen t and approaches unmet needs performing TEVAR in my daily practice.”
The new reduced profile devices continue to feature the GORE® ACTIVE CONTROL System, which facilitates optimized wall apposition even in complex anatomies, such as acute aortic angles. Now, the additional reduced profiles on critical sizes needed allow the device to be introduced through a smaller sheath.
“This milestone is one of several that illustrate our continued dedication to innovate our devices for better long-term patient care,” said Erik Davies, vascular global marketing leader at Gore. “We are proud that we were able to reduce the profile of the GORE® TAG® Conformable Thoracic Stent Graft without changing the design of the device. Patients with smaller vessels are now able to receive the same conformable device that has demonstrated trusted and safe performance for the past 20 years. Maintaining the integrity of the device, Gore’s launch of reduced profiles on critical sizes showcases our continued commitment to developing solutions that advance endovascular solutions for diseases of the aorta.”
The GORE® TAG® Conformable Stent Graft with ACTIVE CONTROL System is part of the growing family of endovascular products that share a mission to effectively treat aortic disease, backed by Gore’s highly rated clinical support team and educational offerings. The portfolio of products includes the GORE® EXCLUDER® AAA Endoprosthesis for the treatment of abdominal aortic aneurysms (AAA), as well as the GORE® EXCLUDER® Conformable AAA Endoprosthesis with ACTIVE CONTROL System , also approved in EU. Together, the GORE EXCLUDER device family is indicated to treat the broadest range of abdominal aortic aneurysms in patients with challenging anatomies. The GORE® EXCLUDER® Iliac Branch Endoprosthesis is approved in EU and is the first FDA-approved, off-the-shelf device for the endovascular treatment of common iliac artery aneurysms or aortoiliac aneurysms, and is indicated for use with the GORE EXCLUDER AAA Endoprosthesis. For potential additions to its branched portfolio, Gore continues to conduct studies on new and novel technologies to treat other aortic disease states.
* Reported outcomes following 5-year-follow-up in FDA PMA clinical
studies.
** Serious adverse events within 30 days of the
procedure. GREAT Post Market Global Registry data collected from 862
patients treated with the Conformable GORE® TAG® Thoracic Endoprosthesis.
MEDICAL PRODUCTS DIVISION
Gore engineers devices that treat a range of cardiovascular and other health conditions. With more than 40 million medical devices implanted over the course of more than 40 years, Gore builds on its legacy of improving patient outcomes through research, education and quality initiatives. Product performance, ease of use and quality of service provide sustainable cost savings for physicians, hospitals and insurers. Gore is joined in service with clinicians and through this collaboration we are improving lives. www.goremedical.com
About Gore
W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Founded in 1958, Gore has built a reputation for solving complex technical challenges in the most demanding environments — from revolutionizing the outerwear industry with GORE-TEX® fabric to creating medical devices that improve and save lives to enabling new levels of performance in the aerospace, pharmaceutical and mobile electronics markets, among other industries. The company is also known for its strong, team-oriented culture and global recognition from the Great Place to Work® Institute. Headquartered in Newark, Del., Gore employs 9,500 Associates and generates annual revenues of $3.5 billion. www.gore.com
Products listed may not be available in all markets.
GORE
®,
GORE-TEX
®, ACTIVE CONTROL, EXCLUDER
®, and TAG
® are
trademarks of W. L. Gore & Associates.
AX1645-EN1
JANUARY
2019
View source version on businesswire.com: https://www.businesswire.com/news/home/20190121005042/en/
Contact:
Media Contacts Bliss Integrated Communication for Gore Medical Nathan Molinari, 646-846-3210 nmolinari@blissintegrated.com or Liz DeForest, 212-584-5477 liz@blissintegrated.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 19:09:00 CET | Press release
PriceRunner v. Google: Sweden’s Largest-Ever Civil Damages Claim Reaches Decision Stage; Klarna Provides Investor Update Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results whi
INRIX Announces New Generation of AI Traffic Products: Helping to Improve Safety, Reduce Congestion, and Enhance Mobility Operations24.2.2026 16:49:00 CET | Press release
New generative AI capabilities, enhanced incident detection, and expanded customer deployments mark a major evolution of the INRIX Traffic product family INRIX, a global leader in transportation data and analytics, today announced a major expansion of its Trafficfamily of products, delivering innovativeAI-driven capabilities to help transportation agencies and logistics organizations move from reactive traffic management to proactive, safety-focused and efficient operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224267928/en/ INRIX introduces expanded automation, generative AI capabilities, enhanced incident detection, and continuous analytics. Over twenty years ago, INRIX commercialized the first system to use GPS data to create real-time traffic information. In 2019, INRIX launched AI Traffic – the world's first traffic platform to leverage deep learning models and AI to improve the quality and analysis globall
Check Point and ControlPlane Partner to Help Enterprises Securely Scale AI and Accelerate Agentic Innovation24.2.2026 15:30:00 CET | Press release
ControlPlane, a specialist AI Security and DevSecOps consultancy, and Check Point Software Technologies Ltd., a pioneer and global leader in cyber security solutions, today announced a strategic collaboration to help enterprises securely adopt Large Language Models (LLMs) and agentic AI systems at scale. The partnership delivers a comprehensive, regulator-ready security framework designed to reduce risk, protect sensitive data, and enable organizations to move confidently from AI experimentation to production deployment. By combining Check Point’s AI-native threat prevention platform with ControlPlane’s deep expertise in cloud native architectures and DevSecOps, enterprises can operationalize AI securely without slowing innovation. As organizations advance AI initiatives beyond pilots, they face a growing “AI readiness gap.” Emerging threats such as prompt injection, unauthorized access, data leakage, and model misuse introduce risks that traditional security controls were not built to
Clinilabs Establishes EU Headquarters in Basel, Strengthening European Clinical Operations Under New Regional Leadership24.2.2026 15:00:00 CET | Press release
Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced the expansion of its European operations, including the establishment of its European Union headquarters at Switzerland Innovation Park Basel Area, and the appointment of Dr. Anne-Marie Nagy as executive vice president and head of Clinilabs Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224669284/en/ Dr. Anne-Marie Nagy appointed as Executive Vice President and Head of Clinilabs Europe Switzerland Innovation Park Basel Area is part of Switzerland’s national innovation network and located within the Basel region’s globally recognized life sciences cluster, bringing together biopharma companies, research institutions, and clinical innovation leaders. “Europe is a critical pillar of Clinilabs’ long-term growth strategy,” said Gary K. Zammit, Ph.D., president and chie
Yubico Unveils “YubiNation Partners”: A New Era of Global Channel Partnership to Secure Digital Identities in the Age of AI24.2.2026 15:00:00 CET | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), a modern cybersecurity company and creator of the most secure passkeys, today announced the launch of YubiNation Partners, a new global Channel program designed to unite a community of security experts. In the face of growing AI-driven cyber threats, the program enables partners to become trusted advisors and cultivate a safer digital world for their customers, making identities private and secure. As the average cost of a corporate security breach climbs to $4.4 million*, with phishing remaining a primary attack vector, the industry can no longer rely on passwords alone. In fact, a 2026 Total Economic Impact study from Forrester Consulting commissioned by Yubico, found that by replacing traditional multi-factor authentication (MFA) and one-time passwords (OTP) with YubiKeys, customers achieved a 265% return on investment (ROI). This effectively eliminated phishing and credential-theft risks, reducing an organization’s risk exposure to breach costs fr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom